Delving into the Latest Updates on Sulforadex with Synapse

ADHD is a neurodevelopmental disorder. It is the most common neurodevelopmental disorder in children and adolescents. Its prevalence is estimated at 5.9% in this population. The symptoms of ADHD combine attention deficit with behavioural disorders such as hyperactivity and impulsivity. Current treatment for ADHD is based on psychotherapeutic and psychoeducational measures aimed at improving behaviour and its impact on the family, social and school environment. Drug treatments may also be used, depending on the impact of the disorder and the effectiveness of alternative treatments. Psychostimulants such as amphetamine derivatives and methylphenidate are around 80% effective.
Sulforaphane is an active substance derived from broccoli that has already been tested in the treatment of other neurodevelopmental disorders. The main hypothesis is that sulforaphane is effective in treating the symptoms of Attention Deficit Disorder with or without Hyperactivity (ADHD) in children.

Start Date01 Dec 2024

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

ACTRN12624000812594

/ RecruitingNot ApplicableIIT

Assessing the effects of a broccoli sprout extract on endothelial function in healthy non-pregnant and pregnant women, and pregnant women with a hypertensive disorder of pregnancy

Start Date01 Nov 2024

Sponsor / Collaborator

Monash Health

100 Clinical Results associated with Sulforadex

Login to view more data

100 Translational Medicine associated with Sulforadex

Login to view more data

100 Patents (Medical) associated with Sulforadex

Login to view more data

4,299

Literatures (Medical) associated with Sulforadex

31 Dec 2025·Epigenetics

An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update

Review

Author: Duttaroy, Asim K. ; Philip, Neha ; Pathak, Surajit ; Siripragada, Sravani ; Banerjee, Antara ; Roy, Susmita ; Deka, Dikshita ; Ayyadurai, Pavithra ; Kondaveeti, Suresh Babu

Colorectal cancer (CRC) remains an alarming global health concern despite advancements in treatment modalities over recent decades. Among the various factors contributing to CRC, this review emphasizes the critical role of epigenetic mechanisms in its pathogenesis and progression. This review also describes the potential role of natural compounds in altering the epigenetic landscape, focused mainly on DNA methylation, histone modification, and non-coding RNAs. Publications from the previous five years were searched and retrieved using well-known search engines and databases like PubMed, Google Scholar, and ScienceDirect. Keywords like CRC/colorectal cancer, CAC/Colitis associated CRC, inflammasomes, epigenetic modulation, genistein, curcumin, quercetin, resveratrol, anthocyanins, sulforaphane, and epigallocatechin-3-gallate were used in various combinations during the search. These natural compounds predominantly affect pathways such as Wnt/β-catenin, NF-κB, and PI3K/AKT to suppress CRC cell proliferation and oxidative stress and enhance anti-inflammation and apoptosis. However, their clinical use is restricted due to their low bioavailability. However, multiple methods exist to overcome challenges like this, including but not limited to structural modifications, nanoparticle encapsulations, bio-enhancers, and novel advanced delivery systems. These methods improve their potential as supportive therapies that target CRC progression epigenetically with fewer side effects. Current research focuses on enhancing epigenetic targeting to control CRC progression while minimizing side effects, emphasizing improved specificity, bioavailability, and efficacy as standalone or synergistic therapies.

31 Dec 2025·Bioengineered

Statement of Retraction: Sulforaphane ameliorates amyloid-β-induced inflammatory injury by suppressing the PARP1/SIRT1 pathway in retinal pigment epithelial cells

Article

01 Dec 2025·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1

Article

Author: Zhang, Chang ; Cao, Deliang ; Hu, Wei ; Xia, Jiliang ; Li, Junjun ; Zhao, Hongyan ; He, Fen ; Sun, Jingqi ; Luo, Cong ; Zeng, Xi ; Lu, Zhongwei ; Sun, Weichu

PURPOSE:

Osteolysis is a common complication in patients with multiple myeloma (MM). Our previous studies have demonstrated that MM cells can promote osteoclast differentiation of macrophages. In this study, we explored the effect of sulforaphane (SFN), a natural NRF2 activator found in broccoli, on MM cell-induced osteoclast differentiation.

METHODS:

Conditional medium (CM) derived from MM cells was used to induce osteoclast differentiation, and TRAP staining was performed to examine osteoclast. Gene expression was detected by western blotting or real-time PCR. Cell counting and EdU staining were performed to test macrophage proliferation.

RESULTS:

We showed that the CM of MM cells downregulated the expression of ferroportin1 (Fpn1), the only known iron exporter in vertebrate cells, thereby increasing cellular iron levels in murine macrophage cells RAW264.7. Deferoxamine (DFO), an iron chelator, effectively blocked MM cell CM-induced osteoclast differentiation and macrophage proliferation, suggesting that iron overload played a key role in these cellular events. Subsequent mechanistic investigations revealed that MM cell CM induced osteoclast differentiation and macrophage proliferation by activating the JNK/AP-1/NFATC1 pathway and PI3K/AKT pathway. SFN was found to increase Fpn1 expression, leading to decreased cellular iron levels in RAW264.7 cells activated by MM cell CM. Importantly, the osteoclast differentiation and macrophage proliferation induced by MM cell CM were significantly inhibited by SFN.

CONCLUSION:

Altogether, our findings indicated that SFN inhibits MM cell-induced osteoclast differentiation and macrophage proliferation by elevating FPN1 levels. SFN could be a promising therapeutic strategy for MM-associated osteolysis.

16

News (Medical) associated with Sulforadex

07 Apr 2025

·www.prnewswire.com

Clinical Study Shows Modulation of Ki-67 Markers by those taking Avmacol® in Former Smokers at High-risk for Lung Cancer

LANCASTER, S.C., April 7, 2025 /PRNewswire/ -- Nutramax Laboratories Consumer Care, Inc. is pleased to share the results of a newly published human clinical study by Yuan et al., in the Cancer Prevention Research journal. The study indicates that Avmacol®, an oral sulforaphane-producing supplement with glucoraphanin and active myrosinase enzyme, is safe and effective at reducing the number of cells with positive Ki-67 in bronchial biopsies in former smokers that are at high-risk for lung cancer. These results significantly add to the growing body of knowledge using Avmacol® as the study product, contributing to the #1 researched sulforaphane-producing brand^. Sulforaphane is an isothiocyanate widely studied for its' detoxification, cellular health, and antioxidant benefits. Sulforaphane is naturally created in the body with glucoraphanin and an active myrosinase enzyme. In this double-blind, placebo-controlled, randomized clinical study, 43 former smokers were assigned to either the sulforaphane (Avmacol®) or placebo group. Subjects in the sulforaphane group took 120 milligrams of glucoraphanin per day for 12 months. One of the primary targets included the Ki-67 index, which is a cancer proliferation marker. Results indicated a 20% decrease of Ki-67 in the sulforaphane group as compared to a 65% increase in the placebo group. "The promising results from this phase II clinical trial provides support for a phase III intervention trial with a large sample size and long-term period to directly examine the efficacy of lung cancer prevention by sulforaphane," said Dr. Jian-Min Yuan, principial investigator on this study from the University of Pittsburgh Medical Center Hillman Cancer Center. The ingredients to make sulforaphane in the body are found in Avmacol® and Avmacol® Extra Strength. The Avmacol® brand is the #1 researched sulforaphane-producing brand^. "This study adds to the rich body of scientific evidence in understanding the nutritional benefits of sulforaphane for targeted care in complex cases," said Meghan Hamrock, MS, MPH, Director of Consumer Marketing and Clinical Nutrition for Nutramax Laboratories Consumer Care, Inc. ABOUT NUTRAMAX LABORATORIES CONSUMER CARE, INC Nutramax Laboratories Consumer Care, Inc. is focused on researching and developing products to promote consumer health. Since its inception in 1992, the Christian-based company has been committed to developing high-quality products. Cosamin® is the #1 researched glucosamine/chondroitin sulfate brand and Avmacol® is the #1 researched sulforaphane-producing brand based on U.S. studies published in peer-reviewed journals. Our products are backed by science and manufactured in world-class facilities at our headquarters in Lancaster, South Carolina where we employ over 800 people nationwide. For more information, visit Avmacol.com or call Customer Service at 888-886-6442. ^ The Avmacol® brand has been selected for use in more sulforaphane human clinical trials than any other sulforaphane-producing supplement. SOURCE Nutramax Laboratories, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 2Phase 3

04 Mar 2024

·www.biospace.com

Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

Latest Patent to Complement Issued Claims on Viral Inhibition, Adaptive Immune Stimulation, and Brain Protection/Regeneration ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers1. The Company was previously awarded by the United States Patent and Trademark Office the following QuadraMune® related patents: Patent #11,229,674, covering inhibition of the immune suppressing enzyme indolamine 2,3 dioxygenase2. It is published that this enzyme plays a fundamental role in immune suppression by cancer3, as well as numerous viruses including SARS-CoV-2, the causative agent of COVID-194. Patent #11,266,707, “Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19”5. Patent #11,504,410, covering use of QuadraMune® and its derivatives for protecting and restoring brain function after neurological damage, including Long COVID6. Patent #11759495, covering upregulation of T regulatory cells for suppression of suicidal ideation7. “In addition to this important validation from the USPTO, the fact that the ingredients in QuadraMune® have been reported by institutions such as Johns Hopkins University to suppress SARS-CoV-2 is strongly encouraging,” said Famela Ramos, Vice President of Business Development for the Company. “Our Company is driven by a desire to address unmet medical needs, whether it is through developing state of the art stem cell and gene therapies, or science-backed nutraceuticals,” said Timothy Dixon, President, and CEO of the Company. “The importance of NK cells in protecting the body against cancer and viruses is well known, the fact that this can be performed using a low-cost nutraceutical approach has implications in both oncology and virology.” About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is . 1 Cerwenka and Lanier. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001 Oct;1(1):41-9. 2 3 Ricuitti et al. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. Pharmacol Ther. 2019 Apr:196:105-116. 4 Guo et al. Indoleamine 2,3-dioxygenase (IDO)-1 and IDO-2 activity and severe course of COVID-19. J Pathol. 2022 Mar;256(3):256-261. 5 6 7 8 Johns Hopkins University Publishes Efficacy of QuadraMune™ Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies | BioSpace

Immunotherapy

17 Jan 2024

·www.pharmaceutical-technology.com

Stalica raises $17.5m to advance neurology programmes

The ASD pipeline consists of 127 drugs spanning all stages of development, with only 7% of drugs present in Phase III and 11.8% in Phase II clinical development. Image Credit: Alex and Maria photo / Shutterstock. Switzerland-based Stalica has raised $17.5m in Series B financing to fund clinical trials for its neuropsychiatric and neurological disorders pipeline. The clinical programmes that the company plans to use the Series B proceeds include the fixed-dose combination drug STP1 and mavoglurant (STP7). Furthermore, the company will also strengthen the data package for STP2. Stalica’s clinical pipeline STP1 is a fixed dose combination of ibudilast, a phosphodiesterase (PDE) 4/3 inhibitor, and bumetanide, a sodium (Na)- potassium (K)- chloride (Cl) cotransporter (NKCC) 1 agonist. Stalica is developing the precision therapy as a treatment for autism spectrum disorder (ASD) in a specific sub-group of patients, phenotype 1 (Phen1). Phen1 patients have been identified by Stalica and validated using two independent clinical observational/bio-sampling studies (NCT05590715 and NCT04644003). The company is planning a Phase II trial for STP1 in patients with ASD, the preparation of which will be funded by the proceeds from the current financing round. Mavoglurant is a negative allosteric modulator of the glutamate receptor 5 (mGluR5). Stalica signed an in-licencing agreement with Novartis to develop the drug as a treatment for substance-use disorders and neurodevelopmental disorders (NDDs) in January 2023. As per the agreement, the company is entitled to receive up to $270m in upfront and milestone-based payments along with royalties on net sales. The company is planning a Phase III trial for mavoglurant in patients with cocaine use disorder in 2025. The trial will be funded by the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH). It is expected to enrol up to 330 patients. STP2 is a stabilised synthetic form of sulforaphane. Stalica acquired the rights to the therapy from the UK-based Evgen Pharma in October 2022. Stalica is developing STP2 as a treatment for ASD in Phen2 sub-population. The company plans to start Phase II trial for the therapy in 2023. ASD landscape The total diagnosed prevalence of ASD was more than 9.81 million in 2023 and is expected to be approximately 9.65 million diagnosed prevalent cases of ASD in 2028, as per a 2023 Globaldata report . The ASD pipeline consists of 127 drugs spanning all stages of development, with only 7% of drugs present in Phase III and 11.8% in Phase II clinical development. GlobalData is the parent company of Pharmaceutical Technology . In November 2023, SciSparc started a clinical trial for SCI-210 to treat ASD symptoms in children. SCI-210 is a combination of cannabidiol (CBD) and palmitoylethanolamide. The trial is expected to enrol 60 patients aged five and 18 years. Apart from ASD treatment, strides have been made in developing diagnostics for the disorder. In September 2023, EarliTech positive data from two studies showing the efficacy and accuracy of its EarliPoint Evaluation device in diagnosing and assessing autism in children aged 30 months and older.

Phase 2Phase 3

100 Deals associated with Sulforadex

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12422

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Distress Syndrome, Adult	Phase 3	United Kingdom	TheraCryf Plc	23 Nov 2020
SARS-CoV-2 acute respiratory disease	Phase 3	United Kingdom	TheraCryf Plc	19 Sep 2020
ER-positive/HER2-negative Breast Cancer	Phase 2	Belgium	-	01 Oct 2016
ER-positive/HER2-negative Breast Cancer	Phase 2	France	-	01 Oct 2016
ER-positive/HER2-negative Breast Cancer	Phase 2	Spain	-	01 Oct 2016
ER-positive/HER2-negative Breast Cancer	Phase 2	United Kingdom	-	01 Oct 2016
Metastatic breast cancer	Phase 2	Belgium	-	01 Oct 2016
Metastatic breast cancer	Phase 2	France	-	01 Oct 2016
Metastatic breast cancer	Phase 2	Spain	-	01 Oct 2016
Metastatic breast cancer	Phase 2	United Kingdom	-	01 Oct 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2025	Not Applicable	Pancreatic adenocarcinoma	-	Non-Thermal Plasma (NTP) + Tirapazamine (TPZ)	ccoolluoqr(fpbtyrimgc) = hvnqytfddu lrrcxfbqgt (vtdjoctxyg ) View more	Positive	28 Apr 2025
NCT03232138 (CTgov)	Phase 2	Lung Cancer	43	Sulforaphane (Sulforaphane (Study Drug))	ciuwtqqjxo(myczxwvdvf) = vuzqxnxkvv kzbpygzffd (nuinxgyyul, 0.38) View more	-	17 Dec 2024
				Placebo (Placebo)	ciuwtqqjxo(myczxwvdvf) = oyezllvtcp kzbpygzffd (nuinxgyyul, 0.41) View more
NCT05153174 (CTgov)	Phase 1	Chronic Kidney Diseases	18	Sulforaphane (2 Tablets of Sulforaphane)	cbealswent(afybwgtxav) = wvttlyseoi uwlchoomew (mtuzrkmvij, 376.5) View more	-	12 Aug 2024
				Sulforaphane (4 Tablets of Sulforaphane)	cbealswent(afybwgtxav) = jdpfnrwxsp uwlchoomew (mtuzrkmvij, 335.8) View more
NCT02614742 (SAS Study, Pubmed)	Phase 2	Subarachnoid Hemorrhage	105	SFX-01 300 mg BD	sauxetgmzy(iohzjinofw) = 9 SFX-01 (16.7%), 1 placebo (2.0%) xsdnsamhjt (qgxkphzxiq )	Negative	19 Jul 2024
ERS2022	Not Applicable	COVID-19	133	S-SFN 300mg	rywdlmlatv(yoikyitymc) = wgtequjlrm anckhntfst (telbznvgrq )	Negative	04 Sep 2022
				Placebo	rywdlmlatv(yoikyitymc) = kznkcxxomv anckhntfst (telbznvgrq )
EASD2021	Not Applicable	-	-	Alpha-cyclodextrin 2g/kg	cpyeybfldx(gfawmujhvy) = pguhztbrcz xaxoysjyth (wqayvcekqi, 4.05)	-	28 Sep 2021
NCT02810964 (CTgov)	Phase 2	Schizoaffective disorder \| Schizophrenia	64	Sulforaphane (Sulforaphane Nutraceutical)	jvalcoxvfl(zrmyxcxdky) = clfltqswrn crvciwbpcy (idgrslpudp, 12.2) View more	-	27 Jul 2021
				Identical-appearing Placebo (Identical-appearing Placebo)	jvalcoxvfl(zrmyxcxdky) = mytazhgjfl crvciwbpcy (idgrslpudp, 13.0) View more
NCT02561481 (Pubmed \| Mol Autism) Manual	Phase 1/2	Autism Spectrum Disorder	57	sulforaphane	oozyoehvxa(lyqqgdiwfp) = cmhaaatzwj utgcrhsshv (lwsofowqks, -0.46 to 0.88) View more	Negative	25 May 2021
				Placebo	oozyoehvxa(lyqqgdiwfp) = uolwrunegz utgcrhsshv (lwsofowqks, -0.52 to 0.72)
NCT02561481 (CTgov)	Phase 1/2	Autism Spectrum Disorder	60	Sulforaphane (Sulforaphane)	eeeagaxtnw(qhkvufnner) = ujxyrjpzbv ifkyutsneg (mwfzxgwypw, 0.67) View more	-	25 Nov 2020
				Placebo (Placebo)	eeeagaxtnw(qhkvufnner) = uuskiijkoc ifkyutsneg (mwfzxgwypw, 0.57) View more
NCT02909959 (CTgov)	Phase 2	Autism Spectrum Disorder \| Autistic Disorder \| Pervasive child development disorders	48	Sulforaphane (Sulforaphane)	icsnhzdzva(jwsruystyr) = arujmremht xvwszqmqmi (seyinztqgg, 7.4) View more	-	15 May 2020
				Placebo (Placebo)	icsnhzdzva(jwsruystyr) = fsrosgncyx xvwszqmqmi (seyinztqgg, 4.6) View more